Cargando…

An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence

Attention deficit hyperactivity disorder (ADHD) impacts significantly on the quality of life (QoL) of patients and their families. Choice of therapy is increasingly influenced by treatment satisfaction and patient preference, with once-daily modified-release methylphenidate (MPH-MR) formulations off...

Descripción completa

Detalles Bibliográficos
Autores principales: Rothenberger, Aribert, Becker, Andreas, Breuer, Dieter, Döpfner, Manfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180635/
https://www.ncbi.nlm.nih.gov/pubmed/21901416
http://dx.doi.org/10.1007/s00787-011-0203-3
_version_ 1782212667192115200
author Rothenberger, Aribert
Becker, Andreas
Breuer, Dieter
Döpfner, Manfred
author_facet Rothenberger, Aribert
Becker, Andreas
Breuer, Dieter
Döpfner, Manfred
author_sort Rothenberger, Aribert
collection PubMed
description Attention deficit hyperactivity disorder (ADHD) impacts significantly on the quality of life (QoL) of patients and their families. Choice of therapy is increasingly influenced by treatment satisfaction and patient preference, with once-daily modified-release methylphenidate (MPH-MR) formulations offering clear benefits compared with immediate-release (IR) dosage forms. The effects of MPH-MR on QoL in ADHD have not been widely investigated and need more clarity in practice. The open-label OBSEER study evaluated the effectiveness and tolerability of Equasym XL(®), a MPH-MR formulation, in routine practice. Children and adolescents (aged 6–17 years) with ADHD and attending school were included if Equasym XL(®) treatment was planned by the treating physician. Physicians, parents and patients completed questionnaires assessing QoL (KINDL; parent, child or adolescent versions), satisfaction with medication, adherence and treatment tolerability at baseline (Visit 1), 1–3 weeks (Visit 2) and 6–12 weeks (Visit 3) over a maximum 3-month observation period. Data from 822 consecutively referred patients were analysed. QoL and medication satisfaction increased from Visit 1 to Visit 3, with both patients and parents rating therapy with Equasym XL(®) as better than previous drug therapy. KINDL total score effect sizes were 0.67 (parents’ ratings), 0.52 (children’s ratings) and 0.51 (adolescents’ ratings; all p < 0.001). All KINDL subscores also increased: both parents and patients had the greatest improvement for school. Adherence to Equasym XL(®) was frequently rated as superior to prior treatment, particularly compared with MPH-IR repeated dosing. Treatment was generally well tolerated; approximately 3% of the patients discontinued treatment due to adverse events. Equasym XL(®) improved QoL compared with prior therapy, and resulted in good medication satisfaction and adherence in drug-naïve and previously treated patients.
format Online
Article
Text
id pubmed-3180635
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-31806352011-10-04 An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence Rothenberger, Aribert Becker, Andreas Breuer, Dieter Döpfner, Manfred Eur Child Adolesc Psychiatry Supplement Attention deficit hyperactivity disorder (ADHD) impacts significantly on the quality of life (QoL) of patients and their families. Choice of therapy is increasingly influenced by treatment satisfaction and patient preference, with once-daily modified-release methylphenidate (MPH-MR) formulations offering clear benefits compared with immediate-release (IR) dosage forms. The effects of MPH-MR on QoL in ADHD have not been widely investigated and need more clarity in practice. The open-label OBSEER study evaluated the effectiveness and tolerability of Equasym XL(®), a MPH-MR formulation, in routine practice. Children and adolescents (aged 6–17 years) with ADHD and attending school were included if Equasym XL(®) treatment was planned by the treating physician. Physicians, parents and patients completed questionnaires assessing QoL (KINDL; parent, child or adolescent versions), satisfaction with medication, adherence and treatment tolerability at baseline (Visit 1), 1–3 weeks (Visit 2) and 6–12 weeks (Visit 3) over a maximum 3-month observation period. Data from 822 consecutively referred patients were analysed. QoL and medication satisfaction increased from Visit 1 to Visit 3, with both patients and parents rating therapy with Equasym XL(®) as better than previous drug therapy. KINDL total score effect sizes were 0.67 (parents’ ratings), 0.52 (children’s ratings) and 0.51 (adolescents’ ratings; all p < 0.001). All KINDL subscores also increased: both parents and patients had the greatest improvement for school. Adherence to Equasym XL(®) was frequently rated as superior to prior treatment, particularly compared with MPH-IR repeated dosing. Treatment was generally well tolerated; approximately 3% of the patients discontinued treatment due to adverse events. Equasym XL(®) improved QoL compared with prior therapy, and resulted in good medication satisfaction and adherence in drug-naïve and previously treated patients. Springer-Verlag 2011-09-08 2011 /pmc/articles/PMC3180635/ /pubmed/21901416 http://dx.doi.org/10.1007/s00787-011-0203-3 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Supplement
Rothenberger, Aribert
Becker, Andreas
Breuer, Dieter
Döpfner, Manfred
An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
title An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
title_full An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
title_fullStr An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
title_full_unstemmed An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
title_short An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence
title_sort observational study of once-daily modified-release methylphenidate in adhd: quality of life, satisfaction with treatment and adherence
topic Supplement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180635/
https://www.ncbi.nlm.nih.gov/pubmed/21901416
http://dx.doi.org/10.1007/s00787-011-0203-3
work_keys_str_mv AT rothenbergeraribert anobservationalstudyofoncedailymodifiedreleasemethylphenidateinadhdqualityoflifesatisfactionwithtreatmentandadherence
AT beckerandreas anobservationalstudyofoncedailymodifiedreleasemethylphenidateinadhdqualityoflifesatisfactionwithtreatmentandadherence
AT breuerdieter anobservationalstudyofoncedailymodifiedreleasemethylphenidateinadhdqualityoflifesatisfactionwithtreatmentandadherence
AT dopfnermanfred anobservationalstudyofoncedailymodifiedreleasemethylphenidateinadhdqualityoflifesatisfactionwithtreatmentandadherence
AT rothenbergeraribert observationalstudyofoncedailymodifiedreleasemethylphenidateinadhdqualityoflifesatisfactionwithtreatmentandadherence
AT beckerandreas observationalstudyofoncedailymodifiedreleasemethylphenidateinadhdqualityoflifesatisfactionwithtreatmentandadherence
AT breuerdieter observationalstudyofoncedailymodifiedreleasemethylphenidateinadhdqualityoflifesatisfactionwithtreatmentandadherence
AT dopfnermanfred observationalstudyofoncedailymodifiedreleasemethylphenidateinadhdqualityoflifesatisfactionwithtreatmentandadherence